La chaîne d'options affiche les données clés des options sur actions de XPeng à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour XPeng..

XPeng (OTC:XPNGF) Stock, Chaîne d'Options

Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

UBS analyst John Hodulik maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Neutral and lowers the price target from $425 to $355.

News

Price Target

Analyst Ratings

CHTR

UBS Maintains Neutral on Charter Communications, Lowers Price Target to $355

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and lowers the price target from $304 to $292.

UBS Maintains Neutral on Chubb, Lowers Price Target to $292

UBS analyst A.J. Rice maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $45 to $31.

UBS Maintains Neutral on Centene, Lowers Price Target to $31

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.28 per share. This is a 7.69 percent increase over earnings of $0.26 per share from the same period last year. The company reported $34.038 million in sales this quarter. This is a 2.81 percent decrease over sales of $35.021 million the same period last year.

Earnings

CORRECTION: National Research Q2 Adj. EPS $0.28 Up From $0.26 YoY, Sales $34.038M Down From $35.021M YoY

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $140 to $136.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $136

Celestica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported financial results for the second quarter on Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/07/g46673477/celestica-announces-second-quarter-2025-financial-results">supply chain solutions company&#8217;s report</a>.
<ul class="wp-block-list">
<li>Q2 Revenue:&nbsp;$2.89 billion, versus&nbsp;<a href="http://benzinga.com/quote/CLS/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $2.65 billion</li>
<li>Q2 Adjusted EPS: $1.39, versus estimates of $1.22</li>
</ul>
Find out how CLS stock is currently doing: <a href="https://www.benzinga.com/quote/CLS" target="_blank" rel="noreferrer noopener">See the chart here.</a>
Total revenue was up 21% on a year-over-year basis, bolstered by &#8220;strong&#8221; adjusted operating margin.
Celestica said it repurchased 600,000 shares of its common stock for $40 million in the quarter. The company ended the period with $313.8 million in cash and cash equivalents.
&#8220;With our strong first half results, and a strengthening demand&nbsp;outlook&nbsp;from our CCS customers, we are increasing our full-year 2025&nbsp;outlook,&#8221; said Rob Mionis, president and CEO of Celestica.
Guidance:&nbsp;Celestica guided for third-quarter revenue of $2.88 billion to $3.13 billion versus estimates of $2.77 billion. The company expects third-quarter adjusted earnings to be in the range of $1.37 to $1.53 per share, versus&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;estimates of $1.28 per share.
Celestica also raised its full-year 2025 outlook. The company now expects 2025 revenue of $11.55 billion, up from prior guidance of $10.85 billion. Celestica sees adjusted earnings of $5.50 per share, up from prior guidance of $5 per share. According to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates, analysts are looking for revenue of $10.95 billion and earnings of $5.02 per share. 
CLS Price Action: <a href="http://benzinga.com/quote/cls" target="_blank" rel="noreferrer noopener">Celestica shares</a> were up 10.17% in after-hours Monday, trading at $191 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46674619/cadence-design-systems-beats-q2-earnings-estimates-raises-fy25-outlook-citing-broad-based-strength-ai-tailwinds">Cadence Design Systems Beats Q2 Earnings Estimates, Raises FY25 Outlook Citing &#8216;Broad-Based Strength,&#8217; AI Tailwinds</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.com

Guidance

Global

After-Hours Center

Movers

Celestica Stock Surges On Q2 Earnings Beat, Company Raises 2025 Outlook On 'Strengthening' Demand

UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Neutral and raises the price target from $17 to $18.

IMVT

UBS Maintains Neutral on Immunovant, Raises Price Target to $18

UBS analyst Damian Karas maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $74 to $76.

UBS Maintains Neutral on A.O. Smith, Raises Price Target to $76

UBS analyst Timothy Arcuri maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and raises the price target from $150 to $210.

UBS Maintains Buy on Advanced Micro Devices, Raises Price Target to $210

Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a <a href="https://www.benzinga.com/pressreleases/25/07/b46675040/fda-informs-sarepta-that-it-recommends-that-sarepta-remove-its-pause-and-resume-shipments-of-elevi">voluntary hold for Elevidys</a>.
What Happened: The FDA announced late Monday that it recommended lifting the voluntary hold on Sarepta Therapeutics&#8217; gene therapy for Duchenne Muscular Dystrophy.&nbsp;The company said in a statement that it was notified by the FDA on Monday and plans to resume shipping Elevidys&nbsp;to sites of care for treatment of ambulatory patients with Duchenne &#8220;imminently.&#8220;
The news comes after the FDA announced on Friday that it was investigating the <a href="https://www.benzinga.com/news/fda/25/07/46657622/fda-probes-death-of-8-year-old-who-received-sareptas-elevidys">death of an 8-year-old</a> in Brazil who had received Elevidys. Sarepta said the FDA determined the death was unlikely to be related to treatment with Elevidys, which is the only approved gene therapy for Duchenne.
&#8220;Last week, at the suggestion of FDA, Sarepta made the difficult decision to pause shipments of ELEVIDYS to provide the FDA with an opportunity to complete a review of available safety information. We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of ELEVIDYS for ambulatory patients,&#8221; said Doug Ingram, CEO of Sarepta Therapeutics.
Sarepta said Elevidys treatment for&nbsp;non-ambulatory patients remains on pause pending the outcome of upcoming discussions with the FDA regarding the company&#8217;s approach to risk-mitigation. 
SRPT Price Action: <a href="http://benzinga.com/quote/SRPT">Sarepta shares</a> closed Monday up 16.18% at $13.86. The stock was briefly halted after-hours. Shares were up 50.57% at $20.87 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46665188/revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow">Revvity Slashes Outlook As China Policy Deals Diagnostics Blow</a></li>
</ul>
Photo: Shutterstock.

Biotech

Health Care

SRPT

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and raises the price target from $37 to $43.

UBS Maintains Neutral on GLOBALFOUNDRIES, Raises Price Target to $43

UBS analyst Stephen Ju maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Neutral and raises the price target from $16 to $18.

TRIP

UBS Maintains Neutral on Tripadvisor, Raises Price Target to $18

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $166 to $182.

EXPE

UBS Maintains Neutral on Expedia Group, Raises Price Target to $182

H2O America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTO#NASDAQ">HTO</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.66 by 14.5 percent. This is a 13.64 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $198.255 million which beat the analyst consensus estimate of $186.643 million by 6.22 percent. This is a 12.53 percent increase over sales of $176.174 million the same period last year.

Earnings Beats

H2O America Q2 Adj. EPS $0.75 Beats $0.66 Estimate, Sales $198.255M Beat $186.643M Estimate

UBS analyst Stephen Ju maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and raises the price target from $5750 to $6300.

BKNG

UBS Maintains Buy on Booking Holdings, Raises Price Target to $6300

The U.S. national debt goes up every minute and with the passage of the One Big Beautiful Bill under President Donald Trump <a href="https://www.benzinga.com/news/politics/25/07/46235830/trump-wants-rate-cuts-will-big-beautiful-bill-help-answer-big-fat-no">could rise even further</a> in the coming years.
American residents are not required to help pay down the debt, but the government does allow that option.
What Happened: A quick look at the <a href="https://www.benzinga.com/topic/national-debt">U.S. National Debt </a>shows a total of $37.16 trillion and counting on Monday.
This <a href="https://www.usdebtclock.org/">translates </a>to around $108,348 per citizen.
Economists believe the national debt can grow under the Big Beautiful Bill by more than $3 trillion.
While costs could go up for consumers, they aren't required to help pay off the national debt.
For those willing to pay off the debt and provide gifts to "reduce the public debt," the government has a <a href="https://www.pay.gov/public/form/start/23779454">website </a>that does just that.
The national government accepts bank accounts and debit or credit cards for payments. Users with a Venmo or PayPal account, which are both owned by PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), can use those accounts to help pay off the national debt.
Read Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46213919/elon-musk-is-100-correct-says-balaji-srinivasan-america-is-broke-and-there-is-no-fix-but-is-it-a-win-win-for-bitcoin">Elon Musk Is 100% Correct, Says Balaji Srinivasan: America Is &#8216;Broke&#8217; And There Is &#8216;No Fix&#8217; But Is It A Win-Win For Bitcoin?</a>
Why It's Important: A <a href="https://x.com/jackcorrbit/status/1948139892720234888">tweet </a>from NPR's Jack Corbett went viral recently with more than six million views on social media platform X. In the post, Corbett said, "You can Venmo the United States to help pay off the national debt."
As <a href="https://www.theverge.com/news/713980/us-national-debt-treasury-department-reduce-pay-venmo">reported </a>by The Verge, the efforts of the government have raised more than a few dollars, too. Since September 1998, <a href="https://fiscaldata.treasury.gov/datasets/gift-contributions-reduce-debt-held-by-public/gift-contributions-to-reduce-the-public-debt">over </a>$67 million has been donated as gifts to help reduce the public national debt.
For many, the tweet was likely out of touch, as most consumers are struggling to pay off their own debt and put money into savings with higher costs of living realized in recent years amid inflation and higher prices at the grocery store.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/financing/25/07/46215083/how-trumps-big-beautiful-bill-impacts-snap-medicaid-taxes-and-student-loans">How Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Impacts SNAP, Medicaid, Taxes, Student Loans</a></li>
</ul>
Photo: viewimage via Shutterstock

Government

Education

PYPL

Want To Help Pay Off $37 Trillion National Debt? Government Accepts Venmo, PayPal

Starcore Intl Mines (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SAM#TSX">SAM</a>) reported quarterly earnings of $0.02 per share. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $9.368 million in sales this quarter. This is a 0.35 percent increase over sales of $9.335 million the same period last year.

TSX:SAM

Starcore Intl Mines Q4 GAAP EPS $0.02 Down From $0.06 YoY, Sales $9.368M Up From $9.335M YoY

UBS analyst Stephen Ju maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $137 to $156.

ABNB

UBS Maintains Neutral on Airbnb, Raises Price Target to $156

UBS analyst Joseph Spak maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Neutral and lowers the price target from $116 to $109.

UBS Maintains Neutral on Lear, Lowers Price Target to $109

UBS analyst Joseph Spak maintains Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Neutral and raises the price target from $23 to $28.

Comments

XPeng

XPeng (XPNGF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL